Aurora B Kinase and Passenger Proteins as Targets for Cancer Therapy
Abstract:The chromosome passenger complex (CPC) is composed of five proteins: Aurora B kinase, Borealin, INCENP, Survivin and TD-60. CPC functions as an oligo-enzyme, each member activating the catalytic subunit, Aurora B kinase.
CPC controls chromosome congression, bidirectional tension on kinetochores and spindle checkpoint signalling as well as cytokinesis completion. CPC is thus a key regulator during mitosis; CPC proteins are exclusively expressed during mitosis and are up-regulated in many tumours. Their overexpression correlates with the level of genomic instability within tumours. Altogether, this leads to the proposal of passenger proteins as potential targets for cancer therapy.
This review describes the chromosomal passenger complex and its involvement in mitosis and the different strategies developed towards its inactivation.
Document Type: Research Article
Publication date: October 1, 2008
More about this publication?
- Current Enzyme Inhibition aims to publish all the latest and outstanding developments in enzyme inhibition studies with regards to the mechanisms of inhibitory processes of enzymes, recognition of active sites, and the discovery of agonists and antagonists, leading to the design and development of new drugs of significant therapeutic value. Each issue contains a series of timely, in-depth reviews written by leaders in the field, covering a range of enzymes that can be exploited for drug development. Current Enzyme Inhibition is an essential journal for every pharmaceutical and medicinal chemist who wishes to have up-to-date knowledge about each and every development in the study of enzyme inhibition.